Kuderer, NM, Dale, DC, Crawford, J. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266.CrossRefGoogle ScholarPubMed

Crawford, J, Dale, DC, Kuderer, NM. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109–118.CrossRefGoogle ScholarPubMed

Lyman, GH, Delgado, DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98(11):2402–2409.CrossRefGoogle ScholarPubMed

Lyman, GH, Morrison, VA, Dale, DC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44(12):2069–2076.CrossRefGoogle ScholarPubMed

Timmer-Bonte, JN, Boo, TM, Smit, HJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23(31):7974–7984.CrossRefGoogle ScholarPubMed

Bonneterre, J, Roche, H, Kerbrat, P. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005;23(12):2686–2693.CrossRefGoogle Scholar

Budman, DR, Berry, DA, Cirrincione, CT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205–1211.CrossRefGoogle ScholarPubMed

Chu, E, DeVita, V. Principles of Medical Oncology. 7th ed. Philadelphia: Lippincott; 2006.Google Scholar

Lyman, GH, Dale, DC, Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531.CrossRefGoogle ScholarPubMed

Lyman, GH, Dale, DC, Friedberg, J. Incidence and predictors of low chemotherapy doseintensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302–4311.CrossRefGoogle ScholarPubMed

Lyman, GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw. 2005;3(4):557–571.CrossRefGoogle Scholar

Balducci, L, Lyman, GH. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol. 2001;19(5):1583–1585.CrossRefGoogle ScholarPubMed

Balducci, L, Yates, J. General guidelines for the management of older patients with cancer. Oncology. 2000;14(11A):221–227.Google ScholarPubMed

Balducci, L, Hardy, CL, Lyman, GH. Hemopoiesis and aging. Cancer Treat Res. 2005;124:109–134.CrossRefGoogle ScholarPubMed

Shank Jr, WA, Balducci, L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc. 1992;40(2):151–154.CrossRefGoogle Scholar

Baker, SD, Grochow, LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13(1):169–183.Google ScholarPubMed

Coiffier, B, Lepage, E, Briere, J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.CrossRefGoogle Scholar

Lyman, GH, Kuderer, N, Agboola, O. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control. 2003;10(6):487–499.CrossRefGoogle ScholarPubMed

Klastersky, J, Paesmans, M, Rubenstein, EB. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051.CrossRefGoogle ScholarPubMed

Lyman, GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7:99–108.CrossRefGoogle ScholarPubMed

Shayne, M, Crawford, J, Dale, DC. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100(3):255–262.CrossRefGoogle ScholarPubMed

Shayne, M, Culakova, E, Poniewierski, MS. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110(7):1611–1620.CrossRefGoogle ScholarPubMed

Aapro, MS, Cameron, DA, Pettengell, R. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433–2453.CrossRefGoogle ScholarPubMed

Crawford, J, Althaus, B, Armitage, J. Myeloid growth factors: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(2):188–202.Google Scholar

Smith, TJ, Khatcheressian, J, Lyman, GH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.CrossRefGoogle ScholarPubMed

Kuderer, NM, Dale, DC, Crawford, J. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167.CrossRefGoogle ScholarPubMed

Wittman, B, Horan, J, Lyman, GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2006;32(4):289–303.CrossRefGoogle ScholarPubMed

Green, MD, Koelbl, H, Baselga, J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.CrossRefGoogle ScholarPubMed

Holmes, FA, O';Shaughnessy, JA, Vukelja, S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–731.CrossRefGoogle ScholarPubMed

Pinto, L, Liu, Z, Doan, Q. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283–2295.CrossRefGoogle ScholarPubMed

Doorduijn, JK, Holt, B, Imhoff, GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3041–3050.CrossRefGoogle ScholarPubMed

Osby, E, Hagberg, H, Kvaloy, S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101(10):3840–3848.CrossRefGoogle ScholarPubMed

Zinzani, PL, Storti, S, Zaccaria, A. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999;94(1):33–38.Google ScholarPubMed

Bohlius, J, Herbst, C, Reiser, M. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;4:CD003189.Google Scholar

Balducci, L, Al-Halawani, H, Charu, V. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12(12):1416–1424.CrossRefGoogle ScholarPubMed

,American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12(11):2471–2508.CrossRefGoogle Scholar

Ozer, H, Armitage, JO, Bennett, CL. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18(20):3558–3585.CrossRefGoogle Scholar

Crawford, J, Althaus, B, Armitage, J. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3(4):540–555.Google Scholar

Crawford, J, Armitage, J, Balducci, L. Myeloid growth factors. J Natl Compr Canc Netw. 2009;7(1):64–83.CrossRefGoogle ScholarPubMed

Repetto, L, Biganzoli, L, Koehne, CH. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39(16):2264–2272.CrossRefGoogle ScholarPubMed

Vogel, CL, Wojtukiewicz, MZ, Carroll, RR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–1184.CrossRefGoogle ScholarPubMed

Lyman, GH, Kleiner, JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw. 2007;5(2):217–228.CrossRefGoogle ScholarPubMed

Balducci, L, Cohen, HJ, Engstrom, PF. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3(4):572–590.Google Scholar

Lyman, GH, Lyman, CH, Agboola, O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427–437.CrossRefGoogle ScholarPubMed

Lyman, GH, Kuderer, NM. The diagnosis and treatment of cancer in the elderly: cost effectiveness considerations. In: Lodovico Balducci, Gary H Lyman, William B Ershler, Martine Extermann, eds. Comprehensive Geriatric Oncology. 2nd ed. London: Taylor and Francis; 2004:pp 510–524.Google Scholar

Lyman, GH, Kuderer, N, Greene, J. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34(12):1857–1864.CrossRefGoogle ScholarPubMed

Lyman, GH, Kuderer, NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1:1–12.CrossRefGoogle ScholarPubMed

Lyman, GH, Kuderer, NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129–146.CrossRefGoogle ScholarPubMed

Lyman, GH, Lyman, CG, Sanderson, RA. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85(6):488–493.CrossRefGoogle ScholarPubMed

Caggiano, V, Weiss, RV, Rickert, TS. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–1924.CrossRefGoogle ScholarPubMed

Eldar-Lissai, A, Cosler, , Culakova, E. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172–179.CrossRefGoogle ScholarPubMed

Ramsey, SD, Liu, Z, Boer, R. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12:217–225.CrossRefGoogle ScholarPubMed

Lyman, G, Lalla, A, Barron, R. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25(2):401–411.CrossRefGoogle ScholarPubMed

Hassett, MJ, O';Malley, AJ, Pakes, JR. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108–1117.CrossRefGoogle Scholar

Cosler, , Calhoun, EA, Agboola, O. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy. 2004;24(4):488–494.CrossRefGoogle ScholarPubMed

Lyman, GH. Time is money for both the healthy and the sick. Med Care. 2005;43(7):637–639.CrossRefGoogle ScholarPubMed

Cosler, , Sivasubramaniam, V, Agboola, O. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health. 2005;8(1): 47–52.CrossRefGoogle ScholarPubMed

Clark, OA, Lyman, GH, Castro, AA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214.CrossRefGoogle ScholarPubMed

Cosler, , Eldar-Lissai, A, Culakova, E. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics. 2007;25(4):343–351.CrossRefGoogle ScholarPubMed

Hershman, D, Neugut, AI, Jacobson, JS. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.CrossRefGoogle ScholarPubMed

Lyman, GH, Dale, DC, Culakova, E. Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review. J Clin Oncol. 2010 (in press).